A new international study led by researchers from UNSW Sydney’s Center for Healthy Brain Aging (CHeBA) has developed the first practical, five-year dementia risk prediction tool for stroke survivors—using only information that’s routinely collected in hospitals and clinics.
Autoimmune diseases such as multiple sclerosis arise when the immune system turns against the body itself. Yet for most of them, it remains unclear why this process begins. Researchers have now identified how the Epstein-Barr virus can, under specific conditions, initiate early multiple sclerosis-like damage in the brain. This offers a new perspective on how rare immune events may shape disease risk.
Sequel Med Tech and Diabeloop today announced a collaboration to integrate a new algorithm into the twiist automated insulin pump.
Select gut bacteria protect mice against post-influenza virus secondary bacterial pneumonia, according to a study published by researchers in the Institute for Biomedical Sciences at Georgia State University.
A new study by the National Cancer Research Center (CNIO) has identified several sets of genes related to the predisposition to develop pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer), as well as the prognosis of the disease once it has appeared.
Sinai Health researchers have shown a blood test that can predict Crohn’s disease years before symptoms appear, opening the doors to early diagnosis and potentially prevention.
Parkinson’s disease (PD) is a debilitating and progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra, a brain region essential for motor control. Clinically, it is marked by tremor, rigidity, bradykinesia and postural instability, symptoms that progressively erode independence and quality of life.
Georgetown University’s Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a superior memory, thereby making them more effective in killing cancer cells.
SAN JOSE, Calif., Jan. 15, 2026 /PRNewswire/ — LEADOPTIK, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Last Inch Assessment™ (LIA) system, the world’s first system to use silicon photonics imaging technology and software designed to improve the accuracy of lung biopsy procedures.
CORAL SPRINGS, Fla., Jan. 12, 2026 /PRNewswire/ — Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved Proliv™Rx, the first prescription, physician-directed, at-home brain neuromodulation therapy as an adjunctive treatment for adults with Major Depressive Disorder (MDD) who failed to achieve satisfactory improvement from at least one previous antidepressant medication.